{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-046651","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.417846+00:00","generated_at":"2026-06-19T03:05:24.044110+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"AlloVir appoints Derek Adams to board; Ansbert Gadicke retires","bullets":["Derek Adams, Ph.D. appointed to Board effective March 1, 2023, filling vacancy from Ansbert Gadicke's retirement.","Dr. Adams brings over 20 years of experience in manufacturing biologic and gene therapies; currently CEO of Stellular Bio.","Ansbert Gadicke, M.D. retires from board effective February 28, 2023; no disagreement with company.","AlloVir is a late-clinical stage allogeneic T cell immunotherapy company with three ongoing Phase 3 studies for posoleucel."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-046651","json":"https://secwatch.observer/filing/0001193125-23-046651.json","markdown":"https://secwatch.observer/filing/0001193125-23-046651.md","text":"https://secwatch.observer/filing/0001193125-23-046651.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523046651/0001193125-23-046651-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523046651/d317019d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T03:05:24.044110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1cc0cc980e","claim":"Ansbert Gadicke retired as Director at Kalaris Therapeutics, Inc..","evidence_excerpt":"Ansbert Gadicke, M.D. notified the Board that he will be retiring from the Board effective February 28, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523046651/0001193125-23-046651-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"5895af1160","claim":"Derek Adams was appointed as Director at Kalaris Therapeutics, Inc..","evidence_excerpt":"the Board appointed Derek Adams, Ph.D. to the Board, effective March 1, 2023, to fill a newly created vacancy resulting from the retirement of Ansbert Gadicke, M.D.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523046651/0001193125-23-046651-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}